INTRODUCTION {#s1}
============

Small cell lung cancer (SCLC) represents 15% of all lung cancers and occurs predominantly in smokers \[[@R1]\]

Due to its rapid doubling time, high growth fraction, and the early development of metastases, only one-third of patients are diagnosed with localized disease \[[@R2]\]. Although SCLC is highly responsive to both chemotherapy and radiotherapy, it commonly relapses within months despite treatment \[[@R3], [@R4]\].

SCLC represents the most aggressive member of a family of tumors with neuroendocrine features such as typical and atypical carcinoids or large cell neuroendocrine carcinomas (LCNEC). Although neuroendocrine characteristics may be difficult to demonstrate in individual cases, a relevant expression of somatostatin receptors (SSTR) on the cell surface has been described \[[@R5], [@R6]\].

The ^68^Ga/^177^Lu/^90^Y-labelled compound DOTATATE/-TOC has been shown to reliably and selectively bind to SSTR2a (and SSTR5). It is widely used in imaging (^68^Ga) and therapy (^177^Lu, ^90^Y) of neuroendocrine tumors \[[@R7], [@R8]\]. The aim of this study was to evaluate the prognostic value of SSTR-expression in patients with advanced SCLC. We further examined pre-requisites for successful peptide receptor radionuclide therapy (PRRT) in this patient group.

RESULTS {#s2}
=======

Patients {#s2_1}
--------

At the time of SSTR-PET/CT, all patients presented with extensive disease and suffered from tumor progression. Metastatic sites included lymph nodes (19/21), liver (10/21), bone (10/21), adrenals (8/21), lung (5/21), brain (4/21), pleura (4/21), pancreas (1/21) and skin (1/21). During follow-up, all patients deceased with 20/21 dying from SCLC and 1 subject from pneumonia. Median PFS was 70 days (range, 2-766 d), median OS 118 days (range, 3-907 d).

SSTR-PET/CT-Imaging {#s2_2}
-------------------

On visual analysis, 4/21 patients were rated "positive" with all SCLC lesions displaying higher tracer uptake than liver parenchyma, 6/21 were rated "intermediate", and 11/21 presented with ^68^Ga-DOTATATE-negative disease (Figure [1](#F1){ref-type="fig"}). The SUV~peak~ values and the T/L ratios of the maximum tumor to mean liver SUV are listed in Table [1](#T1){ref-type="table"}. Both SUV~peak~ values (p\<0.001, Kruskal-Wallis test) and T/L ratios (p\<0.001, Kruskal-Wallis test) were different in the 3 groups. The highest values (SUV \>20, tumor to liver ratio \>2,7) were observed in the 4 patients rated positive with increased uptake in all lesions. SUV~peak~ (9.8±2.5; p=0.01, T-test) and T/L ratios (1.4±0.3; p=0.02, T-test) were lower in the intermediate group and even lower (4.6±1.5 and 0.6±0.2, respectively; p\<0.001 each, T-test) in the negative group.

![Example of SSTR-negative SCLC (patient \#1)\
Maximum intensity projections as well as transaxial slices of FDG- and SSTR-PET/CT are displayed. The patient had multiple hypermetabolic lymph node, intrapulmonary and liver (arrows) lesions which showed intense FDG uptake. In contrast, ^68^Ga-DOTATATE PET demonstrated no relevant expression of somatostatin receptors with the liver metastases presenting as photopenic lesions (arrows).](oncotarget-07-20033-g001){#F1}

###### SUV~peak~ values, T/L ratios of the peak tumor to mean liver SUV and correlation of visual PET results and immunoreactive scores (IRS) for SSTR2a and SSTR5

  Patient   PET            SUVpeak   T/L   SSTR2-IRS   SSTR5-IRS
  --------- -------------- --------- ----- ----------- -----------
  **1**     negative       6.0       0.4   0           0
  **2**     positive       23.3      2.7   9           0
  **3**     intermediate   9.2       1.8   1           0
  **4**     negative       7.2       0.8   N/A         N/A
  **5**     intermediate   10.8      1.1   0           4
  **6**     positive       32.5      4.8   8           0
  **7**     intermediate   14.2      1.3   0           0
  **8**     intermediate   9.1       1.4   8           2
  **9**     positive       35.3      4.5   12          0
  **10**    positive       20.5      2.7   12          2
  **11**    negative       6.2       1.0   0           0
  **12**    intermediate   8.5       1.6   0           0
  **13**    negative       3.6       0.6   2           0
  **14**    negative       4.8       0.8   0           0
  **15**    negative       3.3       0.4   0           0
  **16**    negative       5.4       0.8   0           0
  **17**    intermediate   7.0       0.9   0           0
  **18**    negative       3.9       0.4   1           0
  **19**    negative       2.5       0.4   0           0
  **20**    negative       2.8       0.8   1           0
  **21**    negative       4.9       0.5   N/A         N/A

For quantification of SSTR-positivity at PET, the categories "positive" (all tumor lesions PET-positive with ^68^Ga-DOTATATE uptake \> liver), "intermediate" (the majority of lesions positive) and "negative" (the majority of / all tumor lesions PET-negative) are used. The IRS score is given for histologically assessed SSTR2a/5 expression.

Correlation of ^68^Ga-DOTATATE uptake and histopathology {#s2_3}
--------------------------------------------------------

In 19/21 patients, imaging results could be compared to immunohistological staining for SSTR2a and SSTR5 derived from biopsies of the primary tumor (n=15) or metastases (n=4). Regarding the histological evaluation of SSTR2a expression, 1/19 samples was rated "mild" (IRS 2), 2/19 "moderate" (both IRS 8) and 3/19 "strongly" (one IRS 9, two IRS 12) positive, while 13/19 were scored negative (2/13 with IRS 1 and 11/13 with IRS 0). In contrast, 16/19 samples did not show any SSTR5 expression (all IRS 0), 1/19 was mildly (IRS 2) and 2/19 were moderately (both IRS 4) positive (Table [2](#T2){ref-type="table"}).

###### Patients\' characteristics

  Patient   sex   Age (y)   disease   previous Tx                        Tx post PET   PFS (d)   OS (d)
  --------- ----- --------- --------- ---------------------------------- ------------- --------- --------
  **1**     m     74        LCNEC     RTx                                none          2         5
  **2**     f     74        SCLC      RCTx (1^st^/2^nd^ line)            PRRT (5x)     766       907
  **3**     m     64        SCLC      None                               CTx           161       188
  **4**     f     52        SCLC      RCTx (1^st^/2^nd^ line)            CTx           69        93
  **5**     f     56        SCLC      CTx (1^st^ line)                   CTx           n/a       465
  **6**     m     47        SCLC      RCTx (1^st^/2^nd^ line)            CTx           51        66
  **7**     m     54        SCLC      RCTx (1^st^/2^nd^ line)            CTx           71        95
  **8**     m     67        SCLC      surgery, RCTx (1^st^/2^nd^ line)   CTx           59        126
  **9**     m     69        SCLC      CTx (1^st^/2^nd^ line)             PRRT (1x)     115       118
  **10**    m     66        SCLC      CTx (1^st^/2^nd^ line)             PRRT (1x)     53        53
  **11**    m     51        SCLC      RCTx (1^st^/2^nd^ line)            CTx           26        38
  **12**    f     65        SCLC      RCTx (1^st^/2^nd^ line)            none          8         22
  **13**    m     66        SCLC      RCTx (1^st^ line)                  none          3         3
  **14**    f     52        LCNEC     RCTx (1^st^ line)                  CTx           308       432
  **15**    m     78        LCNEC     CTx (1^st^/2^nd^ line)             CTx           83        118
  **16**    f     62        SCLC      RCTx (1^st^/2^nd^ line)            CTx           324       434
  **17**    m     48        SCLC      RCTx (1^st^/2^nd^ line)            PRRT (6x)     396       575
  **18**    m     51        SCLC      RCTx (1^st^ line)                  CTx           225       239
  **19**    f     69        SCLC      RCTx (1^st^/2^nd^ line)            RTx           8         27
  **20**    f     59        SCLC      RCTx (1^st^ line)                  CTx           85        568
  **21**    f     41        SCLC      RCTx (1^st^ line)                  CTx           63        95

CTx= chemotherapy; f= female; LCNEC= large cell neuroendocrine carcinoma; m= male; OS= overall survival; PFS= progression-free survival; PRRT= peptide receptor radionuclide therapy; RCTx= radio-chemotherapy; RTx= radiotherapy; SCLC= small cell lung cancer. The age of the patients is given in years, OFS and OS in days.

SUV~peak~ as well as the T/L ratios were significantly correlated to the IRS score of SSTR2a expression (Spearman\'s Rho: ρ=0.49 with p=0.03 and ρ=0.61 with p\<0.01, respectively) but not to SSTR5 expression (Spearman\'s Rho: ρ=0.31 with p=0.19 and ρ=0.27 with p=0.27, respectively) (Figure [2](#F2){ref-type="fig"}). In the Kruskal-Wallis test for differences in the groups of PET positivity, no significant differences were found for the SSTR5 IRS score (p=0.2). A difference for the SSTR2a IRS score (p\<0.01) was attributable to a significantly higher score in the 4 patients rated positive with increased uptake in all lesions; no difference was observed between the "intermediate" and "negative" groups (p=0.96, Mann-Whitney test).

![Example of SSTR-directed PET imaging matching immunohistochemical quantification of receptor expression\
Given are maximum intensity projections **A, E.** and immunohistochemical stainings of SCLC patients with high (Patient \# 9, upper row; **C**) and low (patient \#1, lower row; **G**) SSTR 2a expression. SSTR5 expression was low in both samples **D, H.** Positive controls for both SSTR2a and SSTR5 are shown in the inserts in panels **G** and **H.** Counterstaining was performed with hematoxylin **B, F.** Magnification: 200x **B, F.** and 400x **C-H.**](oncotarget-07-20033-g002){#F2}

Interestingly, one patient (patient \#17) had no detectable SSTR-expression in his biopsy sample taken from the primary tumor in the right bronchus consistent with SSTR-PET imaging, but showed high tracer binding in all metastases.

Prognostic value of ^68^Ga-DOTATATE-PET/CT and of SSTR2a-expression {#s2_4}
-------------------------------------------------------------------

Neither the SUV measured with PET/CT nor histological SSTR2a-expression had a prognostic value. Regression analysis (Spearman\'s Rho) yielded SUV~peak~ vs. PFS: ρ=0.04 with p=0.87, SUV~peak~ vs. OS: ρ=0.09 with p=0.71, T/L vs. PFS: ρ=0.13 with p=0.58, T/L vs. OS: ρ=0.17 with p=0.46, SSTR2a IRS score vs. PFS: ρ=0.17 with p=0.49, and SSTR2a IRS score vs. OS: ρ=0.05 with p=0.84.

PRRT {#s2_5}
----

In total, 5/21 patients (4/4 of the positive group and 1/6 of the intermediate group with the vast majority of lesions SSTR-positive) were considered eligible for PRRT. One patient opted for further chemotherapy, leading to a total of 4 SCLC patients undergoing 1, 1, 5 and 6 cycles of PRRT, respectively. Per cycle, 7.6±0.3 GBq of ^177^Lu-DOTATATE (patients \#2, \#9 and \#10) / -DOTATOC (patient \#17) were administered, resulting in cumulative activities of 39.6, 7.4, 7.6, and 44.2 GBq of ^177^Lu, respectively. Treatment was well tolerated by all subjects without any changes in vital signs during therapy or significant therapy-related toxicity. Especially, no kidney failure or myelodysplastic syndrome was observed.

During follow-up, the patient undergoing 5 cycles of PRRT (patient \#2) achieved partial response (Figure [3](#F3){ref-type="fig"}). PFS was 766 days and OS 907 days in patient \#2. The patient with 6 cycles (patient \#17) remained stable for 396 days with a survival of 575 days. One of the two subjects with only 1 cycle of ^177^Lu-DOTATATE reported on an improvement of his overall performance status as well as of his pain (patient \#9). This patient died from pneumonia prior to his second treatment cycle. The remaining patient (patient \#10) did not benefit from radiopeptide therapy and deceased 53 days after PET imaging.

![Example of SSTR-positive SCLC in a patient undergoing PRRT (patient \#2)\
Given are maximum intensity projections as well as transaxial slices of SSTR-PET/CT in an SCLC patient (patient \#2) prior to (left) and after (right) peptide receptor radionuclide therapy (PRRT). The patient had previously undergone 1^st^- (carboplatin/etoposid) and 2^nd^- (topotecan) line chemotherapy and presented with progressive disease. ^68^Ga-DOTATATE PET demonstrated intense expression of somatostatin receptors and SSTR-directed therapy was subsequently performed. After 4 cycles of PRRT, partial response could be recorded.](oncotarget-07-20033-g003){#F3}

DISCUSSION {#s3}
==========

Management of SCLC remains a therapeutic challenge. Whereas cisplatin-based chemotherapeutic regimens are the mainstay of first-line therapy, a number of agents are offered for second-line treatment (usually employing the topoisomerase inhibitor topotecan). A standard third-line therapy has not been defined yet. PRRT has been investigated in this setting as an alternative for patients with high SSTR expression \[[@R9]--[@R11]\]. In our study, we could record a benefit from PRRT in 3 of 4 patients treated: One patient achieved partial response and another patient remained stable for more than a year. Given the median survival of \<12 months in relapsed/refractory SCLC \[[@R12]\], both patients had a very encouraging outcome with an OS of 29 and 18 months, respectively. A third patient reported on improved performance status and pain relief after the first treatment cycle. Unfortunately, he died from pneumonia prior to the scheduled second PRRT.

Important prerequisites to SSTR-targeted therapy are a robust expression of as well as a specific binding to the target receptor. We could demonstrate a good correlation between imaging results and histopathological SSTR2a expression. However, only few patients qualified for PRRT by demonstrating higher receptor expression in tumors than in normal liver parenchyma. In our cohort, only 4 subjects presented with all SCLC lesions SSTR-positive, 6 presented with a mixture of mostly positive but also negative lesions. This finding highlights the phenomenon of tumor heterogeneity with variable features of both primary and metastatic cancer. Though a robust expression of SSTR has been described for SCLC biopsy specimens \[[@R5]\], receptor expression of the metastases can vary. Additionally, the dynamics of SSTR regulation under therapeutic pressure are unknown. Of note, the primary tumor biopsy sample of the patient undergoing the most cycles of PRRT was negative for SSTR expression. One might speculate that SCLC lesions with retained SSTR expression might still harbor more features of better differentiated neuroendocrine tumors and therefore be associated with a better prognosis. However, we did not observe any influence of receptor expression on progression-free or overall survival. SSTR-directed PET/CT cannot serve as a non-invasive prognostic marker. Nevertheless, it can be used as a theranostic means for PRRT assessment.

Achieved tumor doses play an important role in treatment efficacy. In our study, all results were obtained after administration of standard activities of ^177^Lu. Recent in-house dosimetry studies have suggested the feasibility of individualized PRRT with safe administration of higher activities (data not published), possibly resulting in improved outcomes. This study has various limitations. It is retrospective and comprises a very limited number of observations with only 4 patients undergoing radiopeptide therapy. Biopsies were not always obtained in close proximity to PET imaging. However, it is the first report on an anti-tumor effect of SSTR-directed PRRT. Given its excellent tolerability, it can be considered in an otherwise very limited therapeutic scenario. Future research should try to optimize both PRRT procedures (individual dosimetry prior to therapy, shorter intervals between treatment cycles) as well as focus on new potential targets. One of those targets might be represented by chemokine receptor CXCR4, which has been described to be overexpressed in a vast number of malignancies, including SCLC \[[@R13], [@R14]\]. Proof-of-concept for visualization of CXCR4 expression by a radiolabelled PET ligand \[[@R15], [@R16]\] has recently been demonstrated in SCLC patients \[[@R17]\]. As a compound allowing for labelling with various therapeutic α- and β-emitters is available \[[@R18]\], further evaluation of this theranostic approach is warranted.

In conclusion, SSTR-expression as detected by ^68^Ga-DOTATATE and/or histology is not predictive of PFS or OS in patients with advanced SCLC. However, in patients exhibiting sufficient tracer uptake, PRRT might be considered an option given its low toxicity and the absence of effective alternative treatment options. Further research on novel therapeutic targets is warranted.

MATERIALS AND METHODS {#s4}
=====================

Due to the retrospective nature of this study, our institutional review board waived the requirement for informed consent. Still, all patients gave written informed consent to receive SSTR-PET/CT imaging on a compassionate use basis for the purpose of PRRT assessment.

Patients {#s4_1}
--------

Between June 2011 and October 2013, 21 patients (12 males, 9 females, age, 41-74 y) with a history of extensive stage SCLC (n=18) or LCNEC (n=3) were enrolled. All but two patients had completed 1^st^- (cis-/carboplatin/etoposide) and/or 2^nd^-line chemotherapy (topotecan, gemcitabine, ixoten) and showed progressive disease or tumor relapse on CT scans. Detailed patients\' characteristics are given in Table [2](#T2){ref-type="table"}.

After PET/CT, patients were monitored until death with a median follow-up of 3 months (range 0--29 months). Progression-free (PFS) and overall survival (OS) were assessed by serial CT scans (every 3 months) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 \[[@R19]\] and correlated to PET-derived parameters (SUV~peak~, tumor to liver-ratio) as well as to biopsy-derived SSTR2a and SSTR5 expression.

SSTR-PET/CT imaging {#s4_2}
-------------------

PET/CT was performed on an integrated scanner (Siemens Biograph mCT 64, Siemens, Knoxville, USA) consisting of a Lutetium oxyorthosilicate full-ring PET and a 64-slice spiral CT. ^68^Ga-DOTATATE (114 ± 34 MBq) was injected intravenously. After a period of 40-60 min, transmission and PET emission data were acquired as previously described \[[@R20]\].

All imaging tests were reviewed visually by two experienced nuclear medicine physicians (C.L., R.A.W.) who were blinded to clinical data. Patients were categorized according to SSTR-positivity as "positive" (all tumor lesions PET-positive with ^68^Ga-DOTATATE uptake \> liver), "intermediate" (the majority of lesions positive) or "negative" (the majority of / all tumor lesions PET-negative).

For semi-quantitative analysis, peak standardized uptake values (SUV~peak~) were calculated by assigning spherical volumes of interest of 1.5 cm diameter to the area of highest tracer uptake in tumororus tissue. In addition, a 5 cm spherical volume of interest was drawn to healthy tissue of the right lobe of the liver to determine the liver SUV~mean~, serving as reference for background activity. Tumor-to-liver ratios (T/L) were derived.

The 3 patient groups were tested by Kruskal-Wallis analysis for differences regarding the parameters age, SUV~peak~, T/L ratio, PFS, OS, and the IRS scores for the histologically assessed SSTR2a/5 expression.

Immunhistochemical quantification of SSTR-expression {#s4_3}
----------------------------------------------------

In 19/21 patients, imaging results could be compared with histologic SSTR2a and SSTR5 expression of biopsy samples from primary tumors (n=15) or metastases (n=4).

Immunohistochemistry was carried out on 10% formalin fixed paraffin embedded tissue sections according to established protocols with a routine horseradish peroxidase-based labeling technique (ADVANCE; Dako, Hamburg, Germany) and diaminobenzidine as chromogen (DAB+; Dako) and an automated platform (Freedom EVO, Tecan, Crailsheim, Germany). Polyclonal antibodies against SSTR2a (1:500, RBK 046-05, Zytomed, Berlin, Germany) and SSTR5 (1:500, RBK 051-05, Zytomed, Berlin, Germany) were used. Samples from normal pancreatic tissue were used as positive control (islet cells). Dewaxed samples were pretreated with citrate buffer pH 6.0 for 10 minutes (for SSTR2a staining) or respectively with the antigen retrieval agent TIRS-EDTA pH 9.0 for 10 minutes in a high pressure cooker (for SSTR5 staining). All immunostained sections were counterstained for 3 minutes with hematoxylin. The analysis of the stained sections was done semi-quantitatively by light-microscopy according to the immunoreactive score (IRS) by Remmele and Stegner \[[@R21]\]. The percentage of SSTR-positive cells was scored as follows: 0 (no positive cells), 1 (\<10% positive cells), 2 (10-50% positive cells), 3 (\>50-80% positive cells), 4 (\>80% positive cells). Additionally, the intensity of staining was graded: 0 (no color reaction), 1 (mild reaction), 2 (moderate reaction), 3 (intense reaction). Multiplication of both scores for a given sample yields the IRS classification: 0-1 (negative), 2-3 (mild), 4-8 (moderate), 9-12 strongly positive.

PRRT {#s4_4}
----

Peptide receptor radionuclide therapy (including renal protection) was performed according to the joint IAEA, EANM and SNMMI practical guidance \[[@R22]\]. In brief, all patients were hospitalized for a total of 3 days. PRRT with a median of 7.6 GBq (range, 7.2-8.5) of ^177^Lu-DOTATATE/-TOC was intravenously administered over 30 minutes. Vital signs were documented during the infusion and within 7 days after administration. All patients were followed-up after PRRT including serial blood tests, kidney scintigraphy and SSTR-PET/CT. Treatment was performed with an interval of 8-12 weeks between each cycle.

Statistical analysis {#s4_5}
--------------------

Statistical analyses were performed using IBM SPSS (version 23.0). Data were analyzed with non-parametric tests unless the Shapiro-Wilk test indicated compatibility with normal distribution. Quantitative values were expressed as mean ± standard deviation or median and range as appropriate. The tests used are reported together with the results. All statistical tests were performed two-sided and a p-value \< 0.05 was considered to indicate statistical significance.
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